Results 31 to 40 of about 12,698 (210)

Severe Hypoglycemia Due To the Administration of Bromocriptine in a Non-Diabetic Patient: A Case Study

Case Reports in Clinical Practice, 2020
The patient was a 24-year-old man with persistent vegetative state following severe traumatic brain injury due to a car accident, who was referred to the emergency department with a generalized tonic-clonic seizure due to severe hypoglycemia. The patient
Saeed Choobkar, Samad Nazarpoor, Mojgan kaviani   +2 more
doaj   +1 more source

Bromocriptine in the Management of Central Hyperthermia [PDF]

Central fever, or hyperthermia of central origin, is a not so rare cause of hyperthermia in neurological rehabilitation units, characterised by persistent fever without any recognisable cause, and poor response to conventional antipyretics.
Atiq Rehman, Mohammed Hamawi, Krishnaprasad Narayanankutty, Fatma Kuwari   +3 more
core   +1 more source

The regulatory effect of bromocriptine on cardiac hypertrophy by prolactin and D2 receptor modulation

Clinical and Experimental Hypertension, 2020
Background Bromocriptine, a dopamine agonist, used for the treatment of hyperprolactinemia, type 2 diabetes, ovarian hyper-stimulation syndrome, has also effects on the cardiac remodeling process, but the mechanism of action is unknown.
Karla Aidee Aguayo-Cerón, Claudia Camelia Calzada-Mendoza, Enrique Méndez-Bolaina, Rodrigo Romero-Nava, María Esther Ocharan-Hernández   +4 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Bromocriptine-associated ototoxicity [PDF]

, 1984
Three patients treated with bromocriptine for chronic hepatic encephalopathy showed audiometric evidence of bilateral sensori-neural hearing-loss. Audiometrically, the hearing improved in all three patients when the bromocriptine dosage was reduced, thus
Morgan, MY, Ballantyne, J, Lanthier, PL
core  

Novel targets in headache: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra, Peter J. Goadsby, Carolina Oldoni, Stephen Silberstein, Fred Cohen, Simon Akerman   +5 more
wiley   +1 more source

Depot-bromocriptine treatment for prolactinomas and acromegaly.

, 1986
Fifteen patients with hyperprolactinaemia and pituitary macroadenomas (5 patients), microadenomas (6 patients), or acromegaly (4 patients) were given a single intramuscular injection of 50 mg bromocriptine bound to polylactic acid microspheres, depot ...
A. GROSSMAN, R. ROSS, G. M. BESSER, J. A. H. WASS   +3 more
core   +1 more source

Cannabinoid-deficient Benin republic hemp (Cannabis sativa L.) improves semen parameters by reducing prolactin and enhancing anti-oxidant status

BMC Complementary and Alternative Medicine, 2019
Background Nigerian Cannabis sativa (hemp) causes male gonadotoxicity by inducing hyperprolactinemia, down-regulation of hypothalamic-pituitary-testicular axis, and oxidative stress.
Abdullateef Isiaka Alagbonsi, Luqman Aribidesi Olayaki, Halimat Amin Abdulrahim, Thomson Sijuade Adetona, Gbemileke Tobiloba Akinyemi   +4 more
doaj   +1 more source

Impact of ergot alkaloid and steroidal implant on whole-body protein turnover and expression of mTOR pathway proteins in muscle of cattle

Frontiers in Veterinary Science, 2023
IntroductionHolstein steers (n = 32) were used to determine if the ergot analog, bromocriptine decreases muscle protein synthesis through inhibitory action on the mTOR pathway via a direct effect on signal proteins, and if these negative effects can be ...
Taylor D. Ferguson, Caroline M. M. Loos, Eric S. Vanzant, Kristine L. Urschel, James L. Klotz, Kyle R. McLeod   +5 more
doaj   +1 more source

Lack of Efficacy of Low‐Dose Cyclobenzaprine on Electromyographic Activity Related to Sleep Bruxism: A Randomized Crossover Double‐Blind Placebo‐Controlled Clinical Trial

Journal of Sleep Research, EarlyView.
ABSTRACT Sleep bruxism (SB) is a motor activity characterized by repetitive masticatory muscle contractions during sleep, commonly associated with tooth damage and jaw pain or headache. Pharmacological management strategies targeting its central nervous system‐related mechanisms remain limited.
Matheus Herreira‐Ferreira, Cibele Dal Fabbro, Gilles J. Lavigne, Juliana Stuginski‐Barbosa, Peter Svensson, Paulo César Rodrigues Conti, Leonardo Rigoldi Bonjardim   +6 more
wiley   +1 more source